港股異動 | 麗年國際(9918.HK)高開5.59% 成功交付2019冠狀病毒測試對接儀器
格隆匯6月4日丨麗年國際(9918.HK)高開5.59%,報0.189港元,總市值3.78億港元。麗年國際昨日公吿,集團已成功於2021年4月及5月向一間位於美國的定點照護分子診斷公司交付若干用於2019冠狀病毒快速測試的測試儀對接儀器。集團向該客户提供一站式合約製造服務,製造及供應測試儀對接儀器。對接儀器由印刷電路板組件、傳感器、電源線、電子元件及塑膠件組成,為一個用於插入一次性測試盒的平台。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.